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PRECLINICAL RESEARCH
rythropoietin Induces Neovascularization
nd Improves Cardiac Function in Rats
ith Heart Failure After Myocardial Infarction
eter van der Meer, MD,*† Erik Lipsic, MD,*† Robert H. Henning, MD, PHD,† Kristien Boddeus, BSC,†
olanda van der Velden, PHD,‡ Adriaan A. Voors, MD, PHD,* Dirk J. van Veldhuisen, MD, PHD, FACC,*
iek H. van Gilst, PHD,*† Regien G. Schoemaker, PHD†
roningen and Amsterdam, the Netherlands
OBJECTIVES We assessed the effects of erythropoietin (EPO) treatment in a rat model of post-myocardial
infarction (MI) heart failure.
BACKGROUND Erythropoietin, traditionally known as a hematopoietic hormone, has been linked to
neovascularization. Whereas administration of EPO acutely after MI reduces infarct size and
improves cardiac function, its role in the failing heart is unknown.
METHODS Rats underwent coronary ligation or sham surgery. Rats with MI were randomly assigned to:
untreated (MI), a single bolus of EPO immediately after MI induction (MI-EPO–early),
EPO treatment immediately after MI and once every three weeks (MI-EPO–earlylate),
and EPO treatment starting three weeks after induction of MI, once every three weeks
(MI-EPO–late). After nine weeks, hemodynamics, infarct size, myosin heavy chain (MHC)
isoforms, myocyte hypertrophy, and capillary density were measured.
RESULTS Erythropoietin treatment started immediately after MI (MI-EPO–early and MI-EPO–
earlylate) resulted in a 23% to 30% reduction in infarct size (p  0.01) and, accordingly,
hemodynamic improvement. Erythropoietin treatment, started three weeks after MI (MI-
EPO–late), did not affect infarct size, but resulted in an improved cardiac performance,
reflected by a 34% reduction in left ventricular end-diastolic pressure (p  0.01), and 46%
decrease in atrial natriuretic peptide levels (p  0.05). The improved cardiac function was
accompanied by an increased capillary density (p  0.01), an increased capillary-to-myocyte
ratio (p  0.05), and a partial reversal of beta-MHC (p  0.05) in all treated groups.
CONCLUSIONS In addition to its effect on infarct size reduction, EPO treatment improves cardiac function
in a rat model of post-MI heart failure. This observation may be explained by neovascular-
ization, associated with an increased alpha-MHC expression. (J Am Coll Cardiol 2005;46:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.044125–33) © 2005 by the American College of Cardiology Foundation
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arythropoietin (EPO) is best known as a hematopoietic
rowth factor, promoting proliferation and differentiation of
rythroid progenitor cells. However, the expression of the
PO receptor outside the hematopoietic system, including
ndothelial cells, cardiomyocytes, and neurons, may suggest
dditional effects of EPO beyond hematopoiesis (1–4).
Because an insufficient amount of capillaries may lead to
eft ventricular (LV) dilation and heart failure after myocar-
ial infarction (MI) (5), treatment directed towards increas-
ng capillary density might be beneficial in heart failure.
xpanding evidence shows that EPO is involved in angio-
enesis. It has been shown that stimulation of cultured
ndothelial cells with EPO resulted in cell proliferation,
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005, accepted March 15, 2005.hemotaxis, and differentiation into vascular structures (6).
urthermore, Jaquet et al. (7) found that EPO and vascular
ndothelial growth factor were equally effective in stimulat-
ng angiogenesis in endothelial cells derived from the
yocardium. Most recently, it has been shown that EPO
reatment in a rat stroke model resulted in an increased
apillary density around the ischemic lesion (8).
In addition, EPO has been implicated to play a protective
ole during acute ischemia in brain (2,9,10) and heart
11–13). Pretreatment with exogenous EPO rescued hyp-
xic cultured cardiomyocytes from apoptosis (12); EPO
erfusion during ex vivo ischemia-reperfusion improved LV
unction and reduced cellular damage (4,13,14). Acute,
ystemic treatment with EPO, in a rodent ischemia-
eperfusion model, substantially reduced infarct size and
ecreased myocardial apoptosis (12), even when EPO was
dministered after reperfusion (11,15).
While the cardioprotective effects of EPO during acute
I are increasingly recognized, the role of EPO treatment
n chronic heart failure (CHF) is unknown. Therefore, we
ssessed the effects of EPO treatment in a rat model of
ost-MI heart failure (16). In this model, induction of MI
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Erythropoietin Attenuates Heart Failure July 5, 2005:125–33eads to a time-related and infarct size-related ventricular
ilatation and heart failure (17). We hypothesized that
PO treatment initiated after heart failure development
three weeks after induction of MI) would improve cardiac
erformance, possibly by increasing capillary density. To
istinguish the acute effects of EPO (i.e., infarct size
eduction) from its effects in CHF, we studied two addi-
ional groups. In one group we administered only a single
ose of EPO immediately after MI, and in a second group
e administered EPO immediately after MI and continued
PO treatment during the experiment.
ETHODS
nimals. We used male Sprague Dawley rats weighing 270
o 330 g (Harlan, Zeist, the Netherlands). Animals were fed
d libitum, and housed in groups of four to five rats,
ccording to institutional rules with 12:12 h light-dark
ycles. The experimental protocol was approved by the
nimal Ethical Committee of the University of Groningen.
esign of the study. Rats were either subjected to left
oronary artery ligation (n  85) or sham surgery (n  8).
ats with MI were randomized to one of four groups;
ntreated (MI) or three different treatment strategies with
PO: a single bolus of EPO immediately after ligation
MI-EPO–early); EPO treatment directly after ligation and
nce every three weeks (MI-EPO–earlylate); and EPO
reatment starting three weeks after ligation, once every
hree weeks (MI-EPO–late). Erythropoietin (Darbepoetin-
lpha; Aranesp, Amgen Inc., Thousand Oaks, California)
as administered intraperitoneally at a dose of 40 g/kg,
hich equals 8,000 U/kg recombinant human EPO (Am-
en Inc.) and is in close range of known dosages for organ
rotection (11,12,18). Hematocrit was measured at baseline
nd at week one, three, four, six, and nine after surgery.
ersons blinded to the treatment groups performed the
nalysis of samples obtained from the experiments.
I model. This model has been described previously (16).
riefly, rats were anesthetized with 2% isoflurane in 1.0 l
xygen/min. After intubation, the rats were put on a
echanical ventilator (frequency 90/min), and a left-side
horacotomy was performed. Myocardial infarction was
nduced by ligating the proximal portion of the left coronary
Abbreviations and Acronyms
CHF  chronic heart failure
dLVP  developed left ventricular pressure
EPO  erythropoietin
LV  left ventricle/ventricular
LVEDP  left ventricular end-diastolic pressure
LVSP  left ventricular systolic pressure
MHC  myosin heavy chain
MI  myocardial infarction
N-ANP  N-terminal atrial natiuretic peptidertery, beneath the left atrial appendage. In sham-operated nats, the same surgery was performed, without ligating the
uture.
emodynamic measurements. After nine weeks, rats
ere anesthetized as described above. Microtip pressure
ransducer (Millar Instruments Inc., Houston, Texas) was
nserted into the LV cavity via the right carotid artery. After
3-min period of stabilization, heart rate, left ventricular
ystolic pressure (LVSP), left ventricular end-diastolic pres-
ure (LVEDP), and developed left ventricular pressure
dLVP  LVSP  LVEDP) were measured. As indexes of
ontractility and relaxation, the maximal rates of increase
nd decrease in LV pressure (dP/dtmax and dP/dtmax)
ere determined. The catheter was retracted into the aortic
rch, and arterial systolic and diastolic blood pressures were
ecorded.
lasma N-terminal atrial natriuretic peptide (N-ANP)
evels. Arterial blood was collected after nine weeks, anti-
oagulated with EDTA, and plasma was stored at 80°C
ntil assayed. Plasma N-ANP was measured by a commer-
ially available radioimmunoassay (Biotop, Oulu, Finland)
s described previously (19).
nfarct size and LV hypertrophy. After hemodynamic
easurements, hearts were rapidly excised and weighed.
id-papillary slices were prepared for immunohistochem-
stry. Slices were fixed in 4% paraformaldehyde and
araffin-embedded. Infarct size was determined by planim-
try at mid-ventricular levels in transverse slices on picro-
irius red/fast green-stained sections. Infarct size was ex-
ressed as the percentage of scar length to total LV
ircumference, as described previously (20,21). Deparaf-
nized 5-m thick sections were stained with a Gomori’s
ilver staining, in order to visualize individual myocytes in
he viable LV wall, the area with the most pronounced
nderperfusion (22). Using image analysis (Zeiss KS 400,
ena, Germany), concentric myocyte hypertrophy in the
iable LV wall, remote from the infarcted area, was mea-
ured as the cross-sectional area of transversally cut myo-
ytes showing a nucleus. Myocyte density was calculated as
he average number of myocytes per tissue area. In each
tained section, measurements were averaged from three
ifferent counting fields ( 75 myocytes per heart).
yosin heavy chain (MHC) isoform analysis. Samples of
he LV (not infarct area), were frozen in liquid nitrogen and
tored at 80°C. The freeze-dried samples were dissolved
n a buffer, and gel electrophoresis was performed as
escribed previously (23). Samples (0.5 g) were run at
onstant current (24 mA) for 5 h. Silver staining of the gels
nd laser scanning densitometry was performed to identify
ifferences in myosin isoform composition (i.e., alpha-
HC and beta-MHC).
apillary density. To visualize capillaries in the myocar-
ium in the same area as used for the measurements of the
yocyte size, endothelial cells were stained with biotin-
abeled Lectin GSL (1:100; Sigma-Aldrich, St. Louis,
issouri), as previously described (16). Because lectins stainot only capillaries but also other vessels, a size criterion of
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July 5, 2005:125–33 Erythropoietin Attenuates Heart Failure0 m was used to exclude small arterioles and venules.
mage analysis (Image Pro-plus version 4.5, Media Cyber-
etics Inc., Silver Spring, Maryland) was used to measure
apillary density, calculated as the number of capillaries per
issue area. The measured total tissue area was corrected for
he remaining interstitial space. Actual neovascularization
as derived from an increased capillary-to-myocyte ratio,
hich has been calculated as capillary density divided by
yocyte density (24).
tatistical analysis. Data are presented as mean  SEM.
tatistical analysis between groups was performed by one-
ay analysis of variance. When a statistically significant
ifference was detected, a Fisher protected LSD post-hoc
nalysis was performed. Correlation analysis was performed
ith Pearson’s correlation tests. Differences were considered
ignificant at p  0.05.
ESULTS
eneral. Overall mortality after MI was 41%. Mortality
ccurred only in the first 24 h after induction of MI. There
ere no statistically significant differences in mortality
etween the four groups (MI: 50%, MI-EPO–early: 40%,
I-EPO–late: 32%, and MI-EPO–earlylate: 41%; p 
.54). No mortality was observed in sham-operated rats. At
aseline, no differences in body weight were observed (data
ot shown). General characteristics after nine weeks are
hown in Table 1. Body weight was comparable among the
ve groups. Among groups with MI, systolic blood pressure
as significantly lower only in MI and MI-EPO–early
ompared to sham; p  0.01. Systolic blood pressure was
ignificantly higher in MI-EPO–late and MI-EPO–
arlylate compared to MI group (p  0.05). No signifi-
ant differences were observed in heart rate and diastolic
lood pressure, although there was a trend towards higher
iastolic blood pressure in the groups repeatedly treated
able 1. Characteristics of the Experimental Groups
Sham MI
eneral
n 8 12
Infarct size (% of LV) — 43  3
emodynamics
Heart rate (beats/min) 313  3 324  6
SBP (mm Hg) 127  3 111  4†
DBP (mm Hg) 78  2 78  2
ody/organ weight
BW (g) 390  10 395  11
Lung weight/BW (mg/g) 3.9  0.1 6.4  1.0†
Heart weight/BW (mg/g) 3.2  0.1 4.0  0.2†
ematocrit
Baseline (%) 48  0.6 47  0.3
1 week (%) 48  0.6 47  1.1
3 weeks (%) 50  1.1 49  0.7
4 weeks (%) 50  0.5 51  0.8
6 weeks (%) 50  0.4 50  0.7
9 weeks (%) 44  0.5 44  1.5
ata are presented as mean  SEM. *p  0.05; †p  0.01 vs. sham; ‡p  0.05; §
BW  body weight; DBP  diastolic blood pressure; EPO  erythropoietin; LV  left
ressure.ith EPO (MI-EPO–late and MI-EPO–earlylate). The
hanges of the hematocrit throughout the experiment are
lso shown in Table 1. After nine weeks, hematocrit values
ere significantly elevated in the MI-EPO–late and MI-
PO–earlylate compared to other groups.
nfarct size. Left ventricular infarct size (percent of LV)
as comparable between MI and MI-EPO–late, 43% and
1%, respectively (p 0.60; Table 1). Treatment with EPO
mmediately after coronary artery ligation reduced infarct
ize by 30% in MI-EPO–early and by 23% in MI-EPO–
arlylate groups (both p  0.01 vs. MI; Table 1).
emodynamic measurements. Hemodynamic data ob-
ained nine weeks after surgery are summarized in Figure 1.
he LVSP and dLVP were both clearly diminished in MI
ompared to sham-operated rats (p  0.01 for both);
I-EPO–late and MI-EPO–earlylate showed a signifi-
antly higher LVSP and dLVP, compared to MI (all p 
.05). One single bolus of EPO immediately after ligation
MI-EPO–early) did not result in a significantly improved
VSP or dLVP (Figs. 1A and 1B).
The LVEDP was elevated in MI compared to sham-
perated rats (21 3 mm Hg vs. 8 1 mm Hg; p 0.01).
mportantly, EPO treatment started three weeks after MI
MI-EPO–late), resulted in a 34% decrease in LVEDP,
ompared to MI (p  0.01), despite similar infarct sizes.
mmediate treatment with EPO after induction of MI
MI-EPO–early and MI-EPO–earlylate) led to a 27%
nd 38% reduction in LVEDP, respectively, compared to
I group (p  0.05 and p  0.01; Fig. 1C).
Myocardial contractility (dP/dtmax) and myocardial
elaxation (dP/dtmax) were both impaired in MI com-
ared to the sham group (both p  0.01); MI-EPO–late
nd MI-EPO– earlylate showed an improved contrac-
ility and relaxation compared to MI (all p  0.05). In
ontrast, when only one single bolus of EPO was admin-
I-EPO–Early MI-EPO–Late MI-EPO–EarlyLate
12 13 13
30  2§ 41  3 33  2§
332  7 326  7 328  8
115  3† 120  3‡ 122  3‡
79  2 83  3 86  2
401  8 400  7 421  6
4.2  0.5§ 3.9  0.1§ 3.9  0.2§
3.8  0.1† 3.7  0.1* 3.7  0.1*
48  0.5 48  0.6 47  0.6
58  0.9†§ 46  0.7 59  0.7†§
53  0.5†§ 49  0.7 53  0.7†§
50  0.4 62  0.5†§ 64  1.8†§
49  0.6 60  0.7†§ 61  0.7†§
44  0.7 54  1.3†§ 56  1.7†§
.01 vs. MI.M
p  0
ventricle; MI  myocardial infarction; n  number of animals; SBP  systolic blood
i
t
c
N
N
0
l
M
M
M
N
O
1
w
M
L
L
r
A
p
e
s
F
p entric
 #p 
F
0
128 van der Meer et al. JACC Vol. 46, No. 1, 2005
Erythropoietin Attenuates Heart Failure July 5, 2005:125–33stered immediately after MI (MI-EPO– early), contrac-
ility and relaxation were not significantly improved
ompared to MI (Figs. 1D and 1E).
-terminal ANP levels. Figure 2 shows that plasma
-ANP levels were three-fold increased in MI group (p 
.01 vs. sham-operated animals). Furthermore, N-ANP
evels were significantly reduced in the MI-EPO–late and
I-EPO–earlylate groups (p  0.05 and p  0.01 vs.
I), returning to sham values (both p NS vs. sham). The
I-EPO– early group showed a trend towards lower
-ANP levels (p  0.07 vs. MI).
igure 1. Effects of myocardial infarction (MI) and erythropoietin (EPO
ressure; LVEDP  left ventricular end-diastolic pressure; LVSP  left v
decrease of ventricular pressure. *p  0.05 vs. MI; **p  0.01 vs. MI;igure 2. Plasma N-terminal atrial natiuretic peptide (N-terminal ANP) levels.
.01 vs. MI; #p  0.01 vs. sham.rgan weights and LV hypertrophy. As shown in Table
, the ratios of heart weight to body weight and that of lung
eight to body weight were significantly increased in the
I compared to the sham-operated group (both p  0.01).
ung weight to body weight (an indirect expression of the
VEDP and, thus, severity of heart failure) was significantly
educed in all EPO treatment groups (all p  0.01 vs. MI).
trend towards lower heart weight to body weight com-
ared to MI was observed in MI-EPO–late and MI-EPO–
arlylate groups. Left ventricular hypertrophy was further
tudied by histological analysis. Representative photomicro-
tment on hemodynamic parameters. dLVP  developed left ventricular
ular systolic pressure; dP/dtmax  maximal rate of increase; dP/dtmax
0.01 vs. sham.) treaEPO  erythropoietin. *p  0.05 vs. myocardial infarction (MI); **p 
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July 5, 2005:125–33 Erythropoietin Attenuates Heart Failureraphs of Gomori-stained sections of the viable LV free wall
re shown in Figure 3A. Myocardial infarction resulted in a
5% increase in myocyte cross-sectional area, compared to
ham (p  0.05). All EPO-treated groups showed a trend
owards a smaller myocyte cross-sectional area, although
his did not reach statistical significance (Fig. 3B).
ifferences in MHC isoform composition. Relative pro-
ortion of cardiac alpha-MHC and beta-MHC were com-
ared in LV protein samples between the five different
roups. Myocardial infarction resulted in a more than
ve-fold increase in expression of beta-MHC, compared to
ham-operated rats (p  0.01); EPO treatment in all three
roups reduced the expression of beta-MHC by 26% to
1%, compared to MI (p  0.05; Fig. 4).
apillary density. Capillaries stained with lectin were
learly discernable in the myocardium. Figure 5A shows
epresentative photomicrographs of the five different
roups. Capillary density was significantly reduced in the
I group compared to the sham group (p  0.01); EPO
reatment in all three groups prevented the decrease in
apillary density after induction of MI and restored it to
ham values, as shown in Figure 5B (p  NS vs. sham).
urthermore, in the MI-EPO–late and MI-EPO–
arlylate groups, we observed a 39% and 48% increase in
igure 3. (A) Gomori-stained sections in the left ventricular viable wall of
he actual measurements for the myocyte cross-sectional area in the differen0.05 vs. sham.apillary-to-myocyte ratio, respectively (p  0.05 and p 
.01 vs. MI), whereas MI-EPO–early showed a clear trend
p  0.05 vs. MI) towards an increased capillary-to-
yocyte ratio (Fig. 5C).
In order to relate LV functional parameters through an
HC shift to increased capillarization, correlations were
etermined. We observed a strong correlation between
apillary density and beta-MHC expression (r  0.47,
 0.01) and subsequently between beta-MHC expression
nd cardiac contractility and relaxation, r  0.52 and r 
.61, respectively (both p  0.01). Furthermore, capillary
ensity was correlated with myocardial contractility (r 
.32) and relaxation (r  0.37; both p  0.05).
ISCUSSION
n the present study, the effects of EPO treatment in a rat
odel of post-MI heart failure were examined. To our
nowledge, this study shows for the first time that EPO
reatment initiated three weeks after induction of MI results
n an improved cardiac function, as shown by a 17% increase
f dLVP at 34% reduction in LVEDP and a 46% decrease
n N-ANP levels. Furthermore, our data indicate that EPO
ve different groups, showing individual myocytes. (B) Bar graphs showing
erimental groups. EPO  erythropoietin; MI  myocardial infarction. #pthe fi
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Erythropoietin Attenuates Heart Failure July 5, 2005:125–33estores capillary density to sham levels and increases the
apillary-to-myocyte ratio, indicating neovascularization.
yocardial structure and cardiac function. Previous
tudies already revealed that EPO has ancillary properties
esides hematopoiesis. One of the first studies on EPO in
he heart showed that EPO injected intraperitoneally for
even days reduced cardiomyocyte loss by 50% after
igure 4. Effects of myocardial infarction (MI) and erythropoietin (EPO) t
f total MHC expression. *p  0.05 vs. MI; #p  0.01 vs. sham.
igure 5. (A) Tissue sections stained with lectin in the viable free wall of th
2or capillary density in number of capillaries per mm . (C) Bar graphs represent
erythropoietin. *p  0.05 vs. myocardial infarction (MI); **p  0.01 vs. MIschemia-reperfusion injury (25). These observations have
een confirmed by others. Parsa et al. (12) showed a 25%
eduction in infarct size after four days of permanent
cclusion of the left circumflex coronary artery in rabbits. A
ingle dose of EPO at the onset of MI reduced infarct size,
hich was accompanied by reductions in LV size and an
mproved LV ejection fraction, measured by echocardio-
ent on beta-myosin heavy chain (MHC) protein expression as a percentage
different groups, showing individual capillaries. (B) Actual measurementsreatme five
ing the capillary-to-myocyte ratio in the different treatment groups. EPO
; #p  0.01 vs. sham.
g
l
i
3
a
a
t
c
o
c
c
i
i
R
a
p
e
c
m
T
t
r
t
i
B
b
E
fi
N
p
E
h
o
c
a
k
a
t
v
h
f
i
t
c
t
g
n
s
t
i
l
w
l
i
a
t
t
i
i
f
(
w
m
a
E
v
s
m
r
t
a
m
s
H
E
o
r
a
m
s
o
h
e
m
o
h
s
r
fl
r
t
N
w
i
a
d
d
h
d
c
p
i
o
a
a
p
b
131JACC Vol. 46, No. 1, 2005 van der Meer et al.
July 5, 2005:125–33 Erythropoietin Attenuates Heart Failureraphy, during eight weeks follow-up (26). Our results are in
ine with these findings; one single dose of EPO administered
mmediately after induction of MI reduces infarct size by
0% and improves hemodynamics. Mechanisms behind this
cute protective effect of EPO may be related to its
ntiapoptotic effect. We and others (11,12,15,26) showed
hat, in the acute phase of MI, EPO markedly prevents
ardiac cells from undergoing programmed cell death (ap-
ptosis). After MI, apoptosis is first observed in endothelial
ells of small coronary vessels, spreading to the surrounding
ardiomyocytes (27). Because the EPO receptor is predom-
nantly expressed on endothelial cells, preventing apoptosis
n these cells may rescue the underlying myocardium (13).
ecently it has been postulated that cardiac fibroblasts may
lso play a role in the cardioprotective effects of EPO (15).
Although a single dose of EPO clearly improves cardiac
erformance, prolonged EPO treatment (MI-EPO–
arlylate) was associated with a further restoration of
ardiac function. Mechanisms involved in this process are
ost likely distinct from its acute cardioprotective effect.
his is clearly demonstrated by the finding that EPO
reatment, initiated three weeks after MI, although not
educing infarct size, significantly improves cardiac func-
ion, reflected by a 17% increase of dLVP at 34% decrease
n LVEDP, and restoring N-ANP levels to sham values.
ecause the effect of EPO treatment in this group could not
e explained by infarct size reduction, other properties of
PO should be considered to elucidate the observed bene-
cial effects of EPO in heart failure.
eovascularization. Erythropoietin has been shown to
ossess proangiogenic properties. As discussed above, the
PO receptor is expressed on endothelial cells, and EPO
as been shown to stimulate the proliferation and migration
f endothelial cells in vitro (6). Additional experiments in
hick embryos demonstrated that EPO treatment results in
ngiogenesis similar to other well-known angiogenic cyto-
ines (6). Furthermore, EPO induces vascular sprouting in
rat aortic ring model (28). In human cultured myocardial
issue, EPO stimulates capillary outgrowth comparable to
ascular endothelial growth factor (7). In a rodent model of
ind-limb ischemia, EPO increases capillary density 1.6-
old (29). In a rat model of chronic renal failure character-
zed by LV hypertrophy and capillary deficiency, EPO
reatment results only in a small nonsignificant increase in
ardiac capillary density (30). In a rat model of stroke, EPO
reatment, initiated 24 h after infarction, enhances angio-
enesis and improves neurological function, while it does
ot significantly influence infarct size. Our results suggest a
imilar effect of EPO in the heart. We find that EPO
reatment restores capillary density to sham values and
ncreases capillary-to-myocyte ratio, indicating actual capil-
ary growth (24), which is more pronounced in the groups
ith prolonged EPO treatment.
To study the functional consequences of increased capil-
arization, we examined the expression of different MHC
soforms in heart tissue. Cardiomyocytes express both fast tlpha-MHC and slow beta-MHC isoforms, which differ on
he basis of ATPase activity. Recently it has been shown
hat expression of a small amount of alpha-MHC (12%)
n rat cardiomyocytes significantly increases power output,
ndicating that a small shift in MHC composition, as we
ound in all EPO-treated groups, may improve contractility
31). Increased capillary density was significantly correlated
ith the percentage of beta-MHC isoform as well as with
yocardial function (dP/dtmax anddP/dtmax), providing
link between neovascularization and functional effects of
PO.
The mechanism behind the effect of EPO on new blood
essel formation in the heart remains unknown. In general,
timulation of in situ endothelial cell proliferation or bone-
arrow-derived endothelial progenitor cells might play a
ole. Previous work showed that EPO effectively increases
he amount of circulating endothelial progenitor cells (32),
nd significantly induces angiogenesis (29). Future experi-
ents are needed to delineate the mechanism of EPO-
timulated capillary growth.
ematopoietic effect. Another important property of
PO that might be involved in the cardioprotective effect
bserved in our study is its hematopoietic effect. Human
ecombinant EPO increases the number of reticulocytes
fter administration to rats after 3 to 4 days with a
aximum after 8 to 11 days (33). In our study, we observed
ignificant hematocrit elevation one week after a single dose
f EPO. In the groups treated with multiple EPO doses,
ematocrit remained significantly elevated throughout the
xperiment. The beneficial effects seen in these groups
ight, thus, in part, be explained on the basis of increased
xygen-carrying capacity of blood. However, the effects of
igher red blood cell mass on oxygen delivery is not
traightforward, because elevated hematocrit may down-
egulate nitric oxide synthesis and, thus, impair tissue blood
ow (34). In the clinical setting, increasing the number of
ed blood cell mass by blood transfusion has been reported
o improve outcome in elderly patients after acute MI (35).
evertheless, this beneficial effect is only seen in patients
ith hematocrit33%. On the other hand, reduction in the
nfarct size observed in the early treated groups could not be
ttributed to the hematopoietic effect of EPO, because cell
eath and MI expansion occur mainly during the first three
ays after ischemic insult (26) and, thus, before significant
ematocrit elevation.
Conversely, an increase in hematocrit may itself tend to
eteriorate myocardial perfusion through adverse rheologi-
al effects. Elevated hematocrit levels (up to 80%) in
olyglobulic mice, overexpressing EPO, enlarge cerebral
nfarct volumes and leukocyte infiltration after permanent
cclusion of middle cerebral artery (36). Furthermore, EPO
dministration and consequent higher hematocrit has been
ssociated with other adverse cardiovascular effects. Thera-
eutic levels of EPO may cause higher incidence of throm-
osis (37) and could lead to blood pressure elevation (38). In
he present study, rats repeatedly treated with EPO had a
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elated to the improved cardiac function; however, the
ystolic blood pressure remained below the values observed
n the sham-operated group.
linical implications. In clinical settings, EPO treatment
as already been used to correct anemia in patients with
HF. Anemia is frequently observed in patients with CHF
nd related to increased morbidity and mortality (39,40).
urthermore, not only anemia, but also elevated endoge-
ous EPO levels, are independently associated with an
mpaired outcome in CHF (41). Normalization of hemo-
lobin levels in mildly anemic patients with CHF has a
ositive effect on LV ejection fraction (42) and peak VO2
43). In addition to correction of anemia, other nonhema-
opoietic effects of EPO may play a role in the improvement
bserved in patients with CHF treated with EPO.
Besides the treatment of anemia, EPO is currently under
nvestigation for its neuroprotective properties. In the first
linical, randomized, proof-of-concept trial, EPO was given
o patients with ischemic stroke (44); EPO administration
n high doses (entire dose 100,000 IU given in three days)
roved to be both safe and beneficial. Patients randomized
o the EPO group showed significant improvement in
linical outcome parameters and a trend towards smaller
nfarct sizes.
However, chronic therapy with EPO is also associated
ith adverse effects related to hematocrit elevation, such as
ypertension and thromboembolic complications. This
ould be overcome by using a lower dose of EPO, as shown
y Bahlmann et al. (45). In this study, a low dose of
arbepoetin (0.1 g/kg/week) rendered tissue protection in
he kidneys even without raising hematocrit levels. The
ecently discovered nonhematopoietic derivates of EPO
etaining tissue protection but without the undesired effects
n hematopoiesis may become another possibility for
hronic administration (46).
tudy limitations. Several limitations of the present study
ave to be acknowledged. Although a clear increase in
apillary density and capillary-to-myocyte ratio was ob-
erved, the improvement of cardiac function might also be
elated to other effects of EPO treatment. Because we did
ot perform sequential measurements of cardiac function,
urther studies would be needed to specifically denote the
ime-dependent effect of EPO treatment on attenuation of
eart failure development.
We did not measure the direct myocardial perfusion, and,
herefore, functional evidence of an improved perfusion
emains unclear. However, we observed a clear correlation
etween capillary density and beta-MHC expression and
ardiac function. Furthermore, we used the Fisher LSD
ost-hoc statistical test for analyzing our data, which does
ot control for multiple comparisons.
onclusions. In summary, the present study demonstrates
hat EPO treatment in a rat model of heart failure improves
ardiac function beyond its effect on infarct size reduction.
his improvement could be explained by the increasedapillary density and capillary-to-myocyte ratio, indicating
ormation of new blood vessels.
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